Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

The burden of diabetes is high and increasing globally, and predominantly in India, mainly fueled by the increasing ...

The company is still 'evaluating' the price of the drug, but is confident that the price-sensitive Indian population will be able to afford it, Novo's India Managing Director Vikrant Shrotriya said ...

While all eyes are on the Indian industry – known for its ability to produce generic drugs at a fraction of the cost – to ...

Most importantly, younger women have increasingly been diagnosed with breast cancer, a significant risk factor for which was ...

So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...

of Indian men, fell in the obese category that year. A survey conducted by Novo Nordisk, involving over 2,000 people living ...

New CDC population data from 2023 show that in 23 states more than one in three adults (35 percent) has obesity. Before 2013, no state had an adult obesity prevalence at or above 35 percent. Currently ...

Frybread — a simple, versatile “comfort food” for many Indigenous communities — embodies the contradictions that have ...

Obesity is a known precursor to diabetes, hypertension, and cancer -- the non-communicable diseases rising significantly both ...